UBS Group
FOLD

UBS Group’s Amicus Therapeutics FOLD Stock Holding History

UBS Group’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-39,300
Closed -$614K – 8070
2018
Q2 		$614K Buy
+39,300
New +$594K ﹤0.01% 4167
2017
Q4 		– Sell
-5,000
Closed -$75K – 7928
2017
Q3 		$75K Sell
5,000
-20,000
-80% -$265K ﹤0.01% 5518
2017
Q2 		$252K Buy
+25,000
New +$201K ﹤0.01% 4601

Other funds holding FOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

UBS Group's FOLD Position: Q1 2026 in Review

UBS Group increased its Amicus Therapeutics (FOLD) stake by 171% in Q1 2026, buying an estimated $144M and bringing the position to 15,957,913 shares worth $231M. The position accounts for 0.03% of the portfolio, ranked #553.

UBS Group first reported a position in FOLD in Q4 2014 and has held it in 46 quarters since. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

  • UBS Group held 15,957,913 shares of Amicus Therapeutics worth $231M as of Q1 2026.
  • UBS Group bought 10,064,625 Amicus Therapeutics shares in Q1 2026, an estimated $144M.
  • Amicus Therapeutics made up 0.03% of UBS Group's portfolio in Q1 2026, its #553 holding.
  • UBS Group first reported a position in Amicus Therapeutics in Q4 2014 and has held it in 46 quarters since.
  • 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.